nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—ORM1—Tacrolimus—atopic dermatitis	0.109	0.16	CbGbCtD
Erlotinib—ALB—Tacrolimus—atopic dermatitis	0.0457	0.0674	CbGbCtD
Erlotinib—CYP2C8—Mometasone—atopic dermatitis	0.045	0.0664	CbGbCtD
Erlotinib—CYP3A5—Tacrolimus—atopic dermatitis	0.0367	0.0542	CbGbCtD
Erlotinib—CYP1B1—Dexamethasone—atopic dermatitis	0.0353	0.0521	CbGbCtD
Erlotinib—ABCG2—Hydrocortisone—atopic dermatitis	0.027	0.0398	CbGbCtD
Erlotinib—CYP2C8—Loratadine—atopic dermatitis	0.0258	0.0381	CbGbCtD
Erlotinib—CYP3A4—Pimecrolimus—atopic dermatitis	0.0241	0.0355	CbGbCtD
Erlotinib—ABCB1—Tacrolimus—atopic dermatitis	0.0239	0.0353	CbGbCtD
Erlotinib—CYP1A2—Diphenhydramine—atopic dermatitis	0.02	0.0295	CbGbCtD
Erlotinib—ALB—Prednisone—atopic dermatitis	0.0185	0.0273	CbGbCtD
Erlotinib—ABCB1—Loratadine—atopic dermatitis	0.0175	0.0258	CbGbCtD
Erlotinib—ABCG2—Dexamethasone—atopic dermatitis	0.0168	0.0248	CbGbCtD
Erlotinib—CYP2D6—Loratadine—atopic dermatitis	0.0165	0.0243	CbGbCtD
Erlotinib—CYP2D6—Diphenhydramine—atopic dermatitis	0.0165	0.0243	CbGbCtD
Erlotinib—ABCB1—Methylprednisolone—atopic dermatitis	0.016	0.0236	CbGbCtD
Erlotinib—CYP1A1—Dexamethasone—atopic dermatitis	0.0155	0.0229	CbGbCtD
Erlotinib—CYP3A5—Hydrocortisone—atopic dermatitis	0.0149	0.0221	CbGbCtD
Erlotinib—CYP2C8—Hydrocortisone—atopic dermatitis	0.0144	0.0212	CbGbCtD
Erlotinib—CYP3A4—Tacrolimus—atopic dermatitis	0.0143	0.0211	CbGbCtD
Erlotinib—CYP3A4—Loratadine—atopic dermatitis	0.0105	0.0155	CbGbCtD
Erlotinib—ABCB1—Betamethasone—atopic dermatitis	0.0104	0.0153	CbGbCtD
Erlotinib—ABCB1—Prednisolone—atopic dermatitis	0.0103	0.0151	CbGbCtD
Erlotinib—ABCB1—Hydrocortisone—atopic dermatitis	0.00973	0.0144	CbGbCtD
Erlotinib—ABCB1—Prednisone—atopic dermatitis	0.00969	0.0143	CbGbCtD
Erlotinib—CYP3A4—Methylprednisolone—atopic dermatitis	0.00958	0.0141	CbGbCtD
Erlotinib—CYP3A5—Dexamethasone—atopic dermatitis	0.00929	0.0137	CbGbCtD
Erlotinib—CYP2C8—Dexamethasone—atopic dermatitis	0.00894	0.0132	CbGbCtD
Erlotinib—CYP3A4—Triamcinolone—atopic dermatitis	0.00726	0.0107	CbGbCtD
Erlotinib—CYP3A4—Betamethasone—atopic dermatitis	0.00623	0.0092	CbGbCtD
Erlotinib—CYP3A4—Prednisolone—atopic dermatitis	0.00615	0.00907	CbGbCtD
Erlotinib—ABCB1—Dexamethasone—atopic dermatitis	0.00605	0.00893	CbGbCtD
Erlotinib—CYP3A4—Hydrocortisone—atopic dermatitis	0.00583	0.0086	CbGbCtD
Erlotinib—CYP3A4—Prednisone—atopic dermatitis	0.00581	0.00857	CbGbCtD
Erlotinib—CYP2D6—Dexamethasone—atopic dermatitis	0.0057	0.00841	CbGbCtD
Erlotinib—CYP3A4—Dexamethasone—atopic dermatitis	0.00362	0.00535	CbGbCtD
Erlotinib—LTK—head—atopic dermatitis	0.000408	0.0928	CbGeAlD
Erlotinib—NR1I2—head—atopic dermatitis	0.000408	0.0928	CbGeAlD
Erlotinib—AURKC—head—atopic dermatitis	0.000352	0.0801	CbGeAlD
Erlotinib—CYP1A1—skin epidermis—atopic dermatitis	0.000351	0.0798	CbGeAlD
Erlotinib—EPHA6—head—atopic dermatitis	0.000326	0.0742	CbGeAlD
Erlotinib—JAK3—head—atopic dermatitis	0.000326	0.0742	CbGeAlD
Erlotinib—MAP3K19—head—atopic dermatitis	0.000296	0.0674	CbGeAlD
Erlotinib—PIP4K2C—head—atopic dermatitis	0.000232	0.0529	CbGeAlD
Erlotinib—ULK3—head—atopic dermatitis	0.000222	0.0505	CbGeAlD
Erlotinib—MKNK1—head—atopic dermatitis	0.000209	0.0475	CbGeAlD
Erlotinib—Haemorrhage—Triamcinolone—atopic dermatitis	0.000185	0.000725	CcSEcCtD
Erlotinib—Haemorrhage—Methylprednisolone—atopic dermatitis	0.000184	0.000724	CcSEcCtD
Erlotinib—Headache—Fluocinolone Acetonide—atopic dermatitis	0.000184	0.000723	CcSEcCtD
Erlotinib—Acute coronary syndrome—Dexamethasone—atopic dermatitis	0.000184	0.000723	CcSEcCtD
Erlotinib—Acute coronary syndrome—Betamethasone—atopic dermatitis	0.000184	0.000723	CcSEcCtD
Erlotinib—Eye disorder—Hydrocortisone—atopic dermatitis	0.000183	0.00072	CcSEcCtD
Erlotinib—Myocardial infarction—Dexamethasone—atopic dermatitis	0.000183	0.000719	CcSEcCtD
Erlotinib—Myocardial infarction—Betamethasone—atopic dermatitis	0.000183	0.000719	CcSEcCtD
Erlotinib—Neuropathy peripheral—Dexamethasone—atopic dermatitis	0.000183	0.000719	CcSEcCtD
Erlotinib—Neuropathy peripheral—Betamethasone—atopic dermatitis	0.000183	0.000719	CcSEcCtD
Erlotinib—Gastrointestinal pain—Tacrolimus—atopic dermatitis	0.000183	0.000717	CcSEcCtD
Erlotinib—ABL1—skin of body—atopic dermatitis	0.000182	0.0413	CbGeAlD
Erlotinib—Conjunctivitis—Dexamethasone—atopic dermatitis	0.000181	0.000713	CcSEcCtD
Erlotinib—Conjunctivitis—Betamethasone—atopic dermatitis	0.000181	0.000713	CcSEcCtD
Erlotinib—Connective tissue disorder—Methylprednisolone—atopic dermatitis	0.000181	0.000711	CcSEcCtD
Erlotinib—Arrhythmia—Prednisolone—atopic dermatitis	0.000179	0.000705	CcSEcCtD
Erlotinib—Pancreatitis—Prednisone—atopic dermatitis	0.000179	0.000702	CcSEcCtD
Erlotinib—Vomiting—Mometasone—atopic dermatitis	0.000178	0.000701	CcSEcCtD
Erlotinib—Rash—Mometasone—atopic dermatitis	0.000177	0.000695	CcSEcCtD
Erlotinib—Dermatitis—Mometasone—atopic dermatitis	0.000177	0.000694	CcSEcCtD
Erlotinib—Body temperature increased—Tacrolimus—atopic dermatitis	0.000176	0.000693	CcSEcCtD
Erlotinib—Abdominal pain—Tacrolimus—atopic dermatitis	0.000176	0.000693	CcSEcCtD
Erlotinib—Headache—Mometasone—atopic dermatitis	0.000176	0.00069	CcSEcCtD
Erlotinib—Arrhythmia—Hydrocortisone—atopic dermatitis	0.000175	0.000688	CcSEcCtD
Erlotinib—Erythema—Prednisolone—atopic dermatitis	0.000175	0.000687	CcSEcCtD
Erlotinib—Nausea—Fluocinolone Acetonide—atopic dermatitis	0.000174	0.000686	CcSEcCtD
Erlotinib—Eye disorder—Methylprednisolone—atopic dermatitis	0.000172	0.000676	CcSEcCtD
Erlotinib—STK10—head—atopic dermatitis	0.000172	0.0391	CbGeAlD
Erlotinib—Mental disorder—Hydrocortisone—atopic dermatitis	0.000172	0.000675	CcSEcCtD
Erlotinib—Erythema—Hydrocortisone—atopic dermatitis	0.000171	0.00067	CcSEcCtD
Erlotinib—Malnutrition—Hydrocortisone—atopic dermatitis	0.000171	0.00067	CcSEcCtD
Erlotinib—Neutropenia—Prednisone—atopic dermatitis	0.00017	0.000669	CcSEcCtD
Erlotinib—Haemoglobin—Betamethasone—atopic dermatitis	0.000168	0.000661	CcSEcCtD
Erlotinib—Haemoglobin—Dexamethasone—atopic dermatitis	0.000168	0.000661	CcSEcCtD
Erlotinib—Haemorrhage—Dexamethasone—atopic dermatitis	0.000167	0.000658	CcSEcCtD
Erlotinib—Haemorrhage—Betamethasone—atopic dermatitis	0.000167	0.000658	CcSEcCtD
Erlotinib—Nausea—Mometasone—atopic dermatitis	0.000167	0.000655	CcSEcCtD
Erlotinib—Mediastinal disorder—Methylprednisolone—atopic dermatitis	0.000166	0.000652	CcSEcCtD
Erlotinib—Arrhythmia—Triamcinolone—atopic dermatitis	0.000165	0.000648	CcSEcCtD
Erlotinib—Weight decreased—Prednisone—atopic dermatitis	0.000165	0.000648	CcSEcCtD
Erlotinib—Arrhythmia—Methylprednisolone—atopic dermatitis	0.000164	0.000646	CcSEcCtD
Erlotinib—Depression—Prednisone—atopic dermatitis	0.000162	0.000637	CcSEcCtD
Erlotinib—Mental disorder—Methylprednisolone—atopic dermatitis	0.000161	0.000634	CcSEcCtD
Erlotinib—Erythema—Triamcinolone—atopic dermatitis	0.000161	0.000631	CcSEcCtD
Erlotinib—Malnutrition—Methylprednisolone—atopic dermatitis	0.00016	0.00063	CcSEcCtD
Erlotinib—Erythema—Methylprednisolone—atopic dermatitis	0.00016	0.00063	CcSEcCtD
Erlotinib—Asthenia—Tacrolimus—atopic dermatitis	0.00016	0.000629	CcSEcCtD
Erlotinib—Acute coronary syndrome—Prednisone—atopic dermatitis	0.00016	0.000629	CcSEcCtD
Erlotinib—Myocardial infarction—Prednisone—atopic dermatitis	0.000159	0.000626	CcSEcCtD
Erlotinib—Neuropathy peripheral—Prednisone—atopic dermatitis	0.000159	0.000626	CcSEcCtD
Erlotinib—Pruritus—Tacrolimus—atopic dermatitis	0.000158	0.000621	CcSEcCtD
Erlotinib—Syncope—Prednisolone—atopic dermatitis	0.000157	0.000616	CcSEcCtD
Erlotinib—Eye disorder—Dexamethasone—atopic dermatitis	0.000156	0.000615	CcSEcCtD
Erlotinib—Eye disorder—Betamethasone—atopic dermatitis	0.000156	0.000615	CcSEcCtD
Erlotinib—Back pain—Triamcinolone—atopic dermatitis	0.000155	0.000611	CcSEcCtD
Erlotinib—CYP1B1—skin of body—atopic dermatitis	0.000154	0.035	CbGeAlD
Erlotinib—Loss of consciousness—Prednisolone—atopic dermatitis	0.000154	0.000603	CcSEcCtD
Erlotinib—MAP2K5—head—atopic dermatitis	0.000154	0.0349	CbGeAlD
Erlotinib—Syncope—Hydrocortisone—atopic dermatitis	0.000153	0.000601	CcSEcCtD
Erlotinib—Diarrhoea—Tacrolimus—atopic dermatitis	0.000153	0.0006	CcSEcCtD
Erlotinib—Loss of consciousness—Hydrocortisone—atopic dermatitis	0.00015	0.000589	CcSEcCtD
Erlotinib—Arrhythmia—Dexamethasone—atopic dermatitis	0.00015	0.000588	CcSEcCtD
Erlotinib—Arrhythmia—Betamethasone—atopic dermatitis	0.00015	0.000588	CcSEcCtD
Erlotinib—Alopecia—Dexamethasone—atopic dermatitis	0.000148	0.000581	CcSEcCtD
Erlotinib—Alopecia—Betamethasone—atopic dermatitis	0.000148	0.000581	CcSEcCtD
Erlotinib—Dizziness—Tacrolimus—atopic dermatitis	0.000148	0.00058	CcSEcCtD
Erlotinib—Haemoglobin—Prednisone—atopic dermatitis	0.000147	0.000576	CcSEcCtD
Erlotinib—Haemorrhage—Prednisone—atopic dermatitis	0.000146	0.000573	CcSEcCtD
Erlotinib—Erythema—Dexamethasone—atopic dermatitis	0.000146	0.000573	CcSEcCtD
Erlotinib—Erythema—Betamethasone—atopic dermatitis	0.000146	0.000573	CcSEcCtD
Erlotinib—Myalgia—Hydrocortisone—atopic dermatitis	0.000145	0.000571	CcSEcCtD
Erlotinib—Anxiety—Hydrocortisone—atopic dermatitis	0.000145	0.000569	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—atopic dermatitis	0.000144	0.000567	CcSEcCtD
Erlotinib—Syncope—Triamcinolone—atopic dermatitis	0.000144	0.000566	CcSEcCtD
Erlotinib—Syncope—Methylprednisolone—atopic dermatitis	0.000144	0.000565	CcSEcCtD
Erlotinib—Connective tissue disorder—Prednisone—atopic dermatitis	0.000143	0.000563	CcSEcCtD
Erlotinib—Oedema—Prednisolone—atopic dermatitis	0.000143	0.00056	CcSEcCtD
Erlotinib—Vomiting—Tacrolimus—atopic dermatitis	0.000142	0.000558	CcSEcCtD
Erlotinib—Loss of consciousness—Triamcinolone—atopic dermatitis	0.000141	0.000555	CcSEcCtD
Erlotinib—Loss of consciousness—Methylprednisolone—atopic dermatitis	0.000141	0.000554	CcSEcCtD
Erlotinib—Rash—Tacrolimus—atopic dermatitis	0.000141	0.000553	CcSEcCtD
Erlotinib—Dermatitis—Tacrolimus—atopic dermatitis	0.000141	0.000553	CcSEcCtD
Erlotinib—Shock—Prednisolone—atopic dermatitis	0.00014	0.000551	CcSEcCtD
Erlotinib—Cough—Triamcinolone—atopic dermatitis	0.00014	0.000551	CcSEcCtD
Erlotinib—Headache—Tacrolimus—atopic dermatitis	0.00014	0.00055	CcSEcCtD
Erlotinib—Oedema—Hydrocortisone—atopic dermatitis	0.000139	0.000547	CcSEcCtD
Erlotinib—Infection—Hydrocortisone—atopic dermatitis	0.000138	0.000544	CcSEcCtD
Erlotinib—Shock—Hydrocortisone—atopic dermatitis	0.000137	0.000538	CcSEcCtD
Erlotinib—Myalgia—Triamcinolone—atopic dermatitis	0.000137	0.000537	CcSEcCtD
Erlotinib—Nervous system disorder—Hydrocortisone—atopic dermatitis	0.000137	0.000537	CcSEcCtD
Erlotinib—Arthralgia—Methylprednisolone—atopic dermatitis	0.000136	0.000536	CcSEcCtD
Erlotinib—Myalgia—Methylprednisolone—atopic dermatitis	0.000136	0.000536	CcSEcCtD
Erlotinib—Eye disorder—Prednisone—atopic dermatitis	0.000136	0.000536	CcSEcCtD
Erlotinib—Anxiety—Methylprednisolone—atopic dermatitis	0.000136	0.000534	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—atopic dermatitis	0.000136	0.000533	CcSEcCtD
Erlotinib—Skin disorder—Hydrocortisone—atopic dermatitis	0.000135	0.000532	CcSEcCtD
Erlotinib—Anorexia—Hydrocortisone—atopic dermatitis	0.000133	0.000522	CcSEcCtD
Erlotinib—Nausea—Tacrolimus—atopic dermatitis	0.000133	0.000521	CcSEcCtD
Erlotinib—Oedema—Triamcinolone—atopic dermatitis	0.000131	0.000515	CcSEcCtD
Erlotinib—Syncope—Dexamethasone—atopic dermatitis	0.000131	0.000514	CcSEcCtD
Erlotinib—Syncope—Betamethasone—atopic dermatitis	0.000131	0.000514	CcSEcCtD
Erlotinib—Arrhythmia—Prednisone—atopic dermatitis	0.00013	0.000512	CcSEcCtD
Erlotinib—Infection—Triamcinolone—atopic dermatitis	0.00013	0.000512	CcSEcCtD
Erlotinib—Infection—Methylprednisolone—atopic dermatitis	0.00013	0.000511	CcSEcCtD
Erlotinib—Shock—Triamcinolone—atopic dermatitis	0.000129	0.000507	CcSEcCtD
Erlotinib—Insomnia—Prednisolone—atopic dermatitis	0.000129	0.000507	CcSEcCtD
Erlotinib—Alopecia—Prednisone—atopic dermatitis	0.000129	0.000506	CcSEcCtD
Erlotinib—Shock—Methylprednisolone—atopic dermatitis	0.000129	0.000506	CcSEcCtD
Erlotinib—Nervous system disorder—Methylprednisolone—atopic dermatitis	0.000128	0.000504	CcSEcCtD
Erlotinib—Loss of consciousness—Betamethasone—atopic dermatitis	0.000128	0.000503	CcSEcCtD
Erlotinib—Loss of consciousness—Dexamethasone—atopic dermatitis	0.000128	0.000503	CcSEcCtD
Erlotinib—Mental disorder—Prednisone—atopic dermatitis	0.000128	0.000502	CcSEcCtD
Erlotinib—Skin disorder—Methylprednisolone—atopic dermatitis	0.000127	0.000499	CcSEcCtD
Erlotinib—Malnutrition—Prednisone—atopic dermatitis	0.000127	0.000499	CcSEcCtD
Erlotinib—Erythema—Prednisone—atopic dermatitis	0.000127	0.000499	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Hydrocortisone—atopic dermatitis	0.000127	0.000499	CcSEcCtD
Erlotinib—Insomnia—Hydrocortisone—atopic dermatitis	0.000126	0.000495	CcSEcCtD
Erlotinib—Myalgia—Betamethasone—atopic dermatitis	0.000124	0.000488	CcSEcCtD
Erlotinib—Myalgia—Dexamethasone—atopic dermatitis	0.000124	0.000488	CcSEcCtD
Erlotinib—Anxiety—Dexamethasone—atopic dermatitis	0.000124	0.000486	CcSEcCtD
Erlotinib—Anxiety—Betamethasone—atopic dermatitis	0.000124	0.000486	CcSEcCtD
Erlotinib—Dyspepsia—Hydrocortisone—atopic dermatitis	0.000123	0.000482	CcSEcCtD
Erlotinib—Pain—Prednisolone—atopic dermatitis	0.000122	0.000479	CcSEcCtD
Erlotinib—Decreased appetite—Hydrocortisone—atopic dermatitis	0.000121	0.000476	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Hydrocortisone—atopic dermatitis	0.00012	0.000472	CcSEcCtD
Erlotinib—Fatigue—Hydrocortisone—atopic dermatitis	0.00012	0.000472	CcSEcCtD
Erlotinib—SLCO2B1—head—atopic dermatitis	0.000119	0.0272	CbGeAlD
Erlotinib—Musculoskeletal discomfort—Triamcinolone—atopic dermatitis	0.000119	0.000469	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Methylprednisolone—atopic dermatitis	0.000119	0.000468	CcSEcCtD
Erlotinib—Pain—Hydrocortisone—atopic dermatitis	0.000119	0.000468	CcSEcCtD
Erlotinib—Oedema—Dexamethasone—atopic dermatitis	0.000119	0.000468	CcSEcCtD
Erlotinib—Oedema—Betamethasone—atopic dermatitis	0.000119	0.000468	CcSEcCtD
Erlotinib—Insomnia—Triamcinolone—atopic dermatitis	0.000119	0.000466	CcSEcCtD
Erlotinib—ABL1—head—atopic dermatitis	0.000118	0.0269	CbGeAlD
Erlotinib—Insomnia—Methylprednisolone—atopic dermatitis	0.000118	0.000465	CcSEcCtD
Erlotinib—Infection—Betamethasone—atopic dermatitis	0.000118	0.000464	CcSEcCtD
Erlotinib—Infection—Dexamethasone—atopic dermatitis	0.000118	0.000464	CcSEcCtD
Erlotinib—Shock—Betamethasone—atopic dermatitis	0.000117	0.00046	CcSEcCtD
Erlotinib—Shock—Dexamethasone—atopic dermatitis	0.000117	0.00046	CcSEcCtD
Erlotinib—Dyspnoea—Triamcinolone—atopic dermatitis	0.000117	0.000459	CcSEcCtD
Erlotinib—Nervous system disorder—Dexamethasone—atopic dermatitis	0.000117	0.000458	CcSEcCtD
Erlotinib—Nervous system disorder—Betamethasone—atopic dermatitis	0.000117	0.000458	CcSEcCtD
Erlotinib—Thrombocytopenia—Dexamethasone—atopic dermatitis	0.000116	0.000458	CcSEcCtD
Erlotinib—Thrombocytopenia—Betamethasone—atopic dermatitis	0.000116	0.000458	CcSEcCtD
Erlotinib—Dyspepsia—Triamcinolone—atopic dermatitis	0.000115	0.000454	CcSEcCtD
Erlotinib—Dyspepsia—Methylprednisolone—atopic dermatitis	0.000115	0.000453	CcSEcCtD
Erlotinib—Gastrointestinal pain—Hydrocortisone—atopic dermatitis	0.000114	0.000447	CcSEcCtD
Erlotinib—Syncope—Prednisone—atopic dermatitis	0.000114	0.000447	CcSEcCtD
Erlotinib—Anorexia—Dexamethasone—atopic dermatitis	0.000113	0.000446	CcSEcCtD
Erlotinib—Anorexia—Betamethasone—atopic dermatitis	0.000113	0.000446	CcSEcCtD
Erlotinib—Fatigue—Triamcinolone—atopic dermatitis	0.000113	0.000444	CcSEcCtD
Erlotinib—Fatigue—Methylprednisolone—atopic dermatitis	0.000113	0.000443	CcSEcCtD
Erlotinib—Pain—Triamcinolone—atopic dermatitis	0.000112	0.000441	CcSEcCtD
Erlotinib—Loss of consciousness—Prednisone—atopic dermatitis	0.000112	0.000438	CcSEcCtD
Erlotinib—Body temperature increased—Hydrocortisone—atopic dermatitis	0.00011	0.000433	CcSEcCtD
Erlotinib—Abdominal pain—Hydrocortisone—atopic dermatitis	0.00011	0.000433	CcSEcCtD
Erlotinib—CYP1A1—skin of body—atopic dermatitis	0.000109	0.0247	CbGeAlD
Erlotinib—Musculoskeletal discomfort—Dexamethasone—atopic dermatitis	0.000108	0.000426	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Betamethasone—atopic dermatitis	0.000108	0.000426	CcSEcCtD
Erlotinib—Arthralgia—Prednisone—atopic dermatitis	0.000108	0.000425	CcSEcCtD
Erlotinib—Myalgia—Prednisone—atopic dermatitis	0.000108	0.000425	CcSEcCtD
Erlotinib—Anxiety—Prednisone—atopic dermatitis	0.000108	0.000423	CcSEcCtD
Erlotinib—Insomnia—Dexamethasone—atopic dermatitis	0.000108	0.000423	CcSEcCtD
Erlotinib—Insomnia—Betamethasone—atopic dermatitis	0.000108	0.000423	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—atopic dermatitis	0.000107	0.000422	CcSEcCtD
Erlotinib—Gastrointestinal pain—Methylprednisolone—atopic dermatitis	0.000107	0.00042	CcSEcCtD
Erlotinib—Dyspepsia—Betamethasone—atopic dermatitis	0.000105	0.000412	CcSEcCtD
Erlotinib—Dyspepsia—Dexamethasone—atopic dermatitis	0.000105	0.000412	CcSEcCtD
Erlotinib—Body temperature increased—Triamcinolone—atopic dermatitis	0.000104	0.000407	CcSEcCtD
Erlotinib—Oedema—Prednisone—atopic dermatitis	0.000104	0.000407	CcSEcCtD
Erlotinib—Abdominal pain—Methylprednisolone—atopic dermatitis	0.000103	0.000406	CcSEcCtD
Erlotinib—Decreased appetite—Dexamethasone—atopic dermatitis	0.000103	0.000406	CcSEcCtD
Erlotinib—Decreased appetite—Betamethasone—atopic dermatitis	0.000103	0.000406	CcSEcCtD
Erlotinib—Infection—Prednisone—atopic dermatitis	0.000103	0.000404	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Dexamethasone—atopic dermatitis	0.000103	0.000404	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Betamethasone—atopic dermatitis	0.000103	0.000404	CcSEcCtD
Erlotinib—Fatigue—Betamethasone—atopic dermatitis	0.000103	0.000403	CcSEcCtD
Erlotinib—Fatigue—Dexamethasone—atopic dermatitis	0.000103	0.000403	CcSEcCtD
Erlotinib—Shock—Prednisone—atopic dermatitis	0.000102	0.000401	CcSEcCtD
Erlotinib—Pain—Betamethasone—atopic dermatitis	0.000102	0.0004	CcSEcCtD
Erlotinib—Pain—Dexamethasone—atopic dermatitis	0.000102	0.0004	CcSEcCtD
Erlotinib—Nervous system disorder—Prednisone—atopic dermatitis	0.000102	0.000399	CcSEcCtD
Erlotinib—Skin disorder—Prednisone—atopic dermatitis	0.000101	0.000395	CcSEcCtD
Erlotinib—CYP1B1—head—atopic dermatitis	0.0001	0.0228	CbGeAlD
Erlotinib—Asthenia—Hydrocortisone—atopic dermatitis	9.99e-05	0.000393	CcSEcCtD
Erlotinib—Anorexia—Prednisone—atopic dermatitis	9.87e-05	0.000388	CcSEcCtD
Erlotinib—Pruritus—Hydrocortisone—atopic dermatitis	9.85e-05	0.000387	CcSEcCtD
Erlotinib—Gastrointestinal pain—Dexamethasone—atopic dermatitis	9.73e-05	0.000382	CcSEcCtD
Erlotinib—Gastrointestinal pain—Betamethasone—atopic dermatitis	9.73e-05	0.000382	CcSEcCtD
Erlotinib—Diarrhoea—Hydrocortisone—atopic dermatitis	9.53e-05	0.000374	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Prednisone—atopic dermatitis	9.44e-05	0.000371	CcSEcCtD
Erlotinib—Dizziness—Prednisolone—atopic dermatitis	9.43e-05	0.000371	CcSEcCtD
Erlotinib—Asthenia—Triamcinolone—atopic dermatitis	9.41e-05	0.00037	CcSEcCtD
Erlotinib—Abdominal pain—Betamethasone—atopic dermatitis	9.4e-05	0.00037	CcSEcCtD
Erlotinib—Body temperature increased—Betamethasone—atopic dermatitis	9.4e-05	0.00037	CcSEcCtD
Erlotinib—Abdominal pain—Dexamethasone—atopic dermatitis	9.4e-05	0.00037	CcSEcCtD
Erlotinib—Body temperature increased—Dexamethasone—atopic dermatitis	9.4e-05	0.00037	CcSEcCtD
Erlotinib—Asthenia—Methylprednisolone—atopic dermatitis	9.39e-05	0.000369	CcSEcCtD
Erlotinib—Insomnia—Prednisone—atopic dermatitis	9.37e-05	0.000368	CcSEcCtD
Erlotinib—Pruritus—Triamcinolone—atopic dermatitis	9.28e-05	0.000365	CcSEcCtD
Erlotinib—Pruritus—Methylprednisolone—atopic dermatitis	9.25e-05	0.000364	CcSEcCtD
Erlotinib—Dizziness—Hydrocortisone—atopic dermatitis	9.21e-05	0.000362	CcSEcCtD
Erlotinib—Dyspepsia—Prednisone—atopic dermatitis	9.12e-05	0.000358	CcSEcCtD
Erlotinib—Decreased appetite—Prednisone—atopic dermatitis	9.01e-05	0.000354	CcSEcCtD
Erlotinib—Rash—Prednisolone—atopic dermatitis	8.99e-05	0.000353	CcSEcCtD
Erlotinib—Dermatitis—Prednisolone—atopic dermatitis	8.98e-05	0.000353	CcSEcCtD
Erlotinib—Diarrhoea—Methylprednisolone—atopic dermatitis	8.95e-05	0.000352	CcSEcCtD
Erlotinib—Fatigue—Prednisone—atopic dermatitis	8.93e-05	0.000351	CcSEcCtD
Erlotinib—Headache—Prednisolone—atopic dermatitis	8.93e-05	0.000351	CcSEcCtD
Erlotinib—Constipation—Prednisone—atopic dermatitis	8.86e-05	0.000348	CcSEcCtD
Erlotinib—Vomiting—Hydrocortisone—atopic dermatitis	8.85e-05	0.000348	CcSEcCtD
Erlotinib—Rash—Hydrocortisone—atopic dermatitis	8.78e-05	0.000345	CcSEcCtD
Erlotinib—Dermatitis—Hydrocortisone—atopic dermatitis	8.77e-05	0.000345	CcSEcCtD
Erlotinib—Headache—Hydrocortisone—atopic dermatitis	8.72e-05	0.000343	CcSEcCtD
Erlotinib—Dizziness—Triamcinolone—atopic dermatitis	8.67e-05	0.000341	CcSEcCtD
Erlotinib—Dizziness—Methylprednisolone—atopic dermatitis	8.65e-05	0.00034	CcSEcCtD
Erlotinib—Asthenia—Betamethasone—atopic dermatitis	8.53e-05	0.000335	CcSEcCtD
Erlotinib—Asthenia—Dexamethasone—atopic dermatitis	8.53e-05	0.000335	CcSEcCtD
Erlotinib—Gastrointestinal pain—Prednisone—atopic dermatitis	8.47e-05	0.000333	CcSEcCtD
Erlotinib—Nausea—Prednisolone—atopic dermatitis	8.47e-05	0.000333	CcSEcCtD
Erlotinib—Pruritus—Dexamethasone—atopic dermatitis	8.42e-05	0.000331	CcSEcCtD
Erlotinib—Pruritus—Betamethasone—atopic dermatitis	8.42e-05	0.000331	CcSEcCtD
Erlotinib—Vomiting—Triamcinolone—atopic dermatitis	8.34e-05	0.000328	CcSEcCtD
Erlotinib—Vomiting—Methylprednisolone—atopic dermatitis	8.32e-05	0.000327	CcSEcCtD
Erlotinib—Nausea—Hydrocortisone—atopic dermatitis	8.27e-05	0.000325	CcSEcCtD
Erlotinib—Rash—Triamcinolone—atopic dermatitis	8.27e-05	0.000325	CcSEcCtD
Erlotinib—Dermatitis—Triamcinolone—atopic dermatitis	8.26e-05	0.000325	CcSEcCtD
Erlotinib—Rash—Methylprednisolone—atopic dermatitis	8.25e-05	0.000324	CcSEcCtD
Erlotinib—Dermatitis—Methylprednisolone—atopic dermatitis	8.24e-05	0.000324	CcSEcCtD
Erlotinib—Headache—Triamcinolone—atopic dermatitis	8.21e-05	0.000323	CcSEcCtD
Erlotinib—Headache—Methylprednisolone—atopic dermatitis	8.19e-05	0.000322	CcSEcCtD
Erlotinib—Abdominal pain—Prednisone—atopic dermatitis	8.19e-05	0.000322	CcSEcCtD
Erlotinib—Body temperature increased—Prednisone—atopic dermatitis	8.19e-05	0.000322	CcSEcCtD
Erlotinib—Diarrhoea—Dexamethasone—atopic dermatitis	8.14e-05	0.00032	CcSEcCtD
Erlotinib—Diarrhoea—Betamethasone—atopic dermatitis	8.14e-05	0.00032	CcSEcCtD
Erlotinib—Dizziness—Betamethasone—atopic dermatitis	7.87e-05	0.000309	CcSEcCtD
Erlotinib—Dizziness—Dexamethasone—atopic dermatitis	7.87e-05	0.000309	CcSEcCtD
Erlotinib—Nausea—Triamcinolone—atopic dermatitis	7.79e-05	0.000306	CcSEcCtD
Erlotinib—Nausea—Methylprednisolone—atopic dermatitis	7.77e-05	0.000305	CcSEcCtD
Erlotinib—Vomiting—Betamethasone—atopic dermatitis	7.56e-05	0.000297	CcSEcCtD
Erlotinib—Vomiting—Dexamethasone—atopic dermatitis	7.56e-05	0.000297	CcSEcCtD
Erlotinib—Rash—Betamethasone—atopic dermatitis	7.5e-05	0.000295	CcSEcCtD
Erlotinib—Rash—Dexamethasone—atopic dermatitis	7.5e-05	0.000295	CcSEcCtD
Erlotinib—Dermatitis—Betamethasone—atopic dermatitis	7.49e-05	0.000294	CcSEcCtD
Erlotinib—Dermatitis—Dexamethasone—atopic dermatitis	7.49e-05	0.000294	CcSEcCtD
Erlotinib—Headache—Dexamethasone—atopic dermatitis	7.45e-05	0.000293	CcSEcCtD
Erlotinib—Headache—Betamethasone—atopic dermatitis	7.45e-05	0.000293	CcSEcCtD
Erlotinib—Asthenia—Prednisone—atopic dermatitis	7.43e-05	0.000292	CcSEcCtD
Erlotinib—Pruritus—Prednisone—atopic dermatitis	7.33e-05	0.000288	CcSEcCtD
Erlotinib—CYP1A1—head—atopic dermatitis	7.09e-05	0.0161	CbGeAlD
Erlotinib—Diarrhoea—Prednisone—atopic dermatitis	7.09e-05	0.000279	CcSEcCtD
Erlotinib—Nausea—Dexamethasone—atopic dermatitis	7.07e-05	0.000278	CcSEcCtD
Erlotinib—Nausea—Betamethasone—atopic dermatitis	7.07e-05	0.000278	CcSEcCtD
Erlotinib—Dizziness—Prednisone—atopic dermatitis	6.85e-05	0.000269	CcSEcCtD
Erlotinib—Vomiting—Prednisone—atopic dermatitis	6.59e-05	0.000259	CcSEcCtD
Erlotinib—Rash—Prednisone—atopic dermatitis	6.53e-05	0.000257	CcSEcCtD
Erlotinib—Dermatitis—Prednisone—atopic dermatitis	6.53e-05	0.000256	CcSEcCtD
Erlotinib—Headache—Prednisone—atopic dermatitis	6.49e-05	0.000255	CcSEcCtD
Erlotinib—Nausea—Prednisone—atopic dermatitis	6.15e-05	0.000242	CcSEcCtD
Erlotinib—CYP2D6—head—atopic dermatitis	5.12e-05	0.0116	CbGeAlD
Erlotinib—EGFR—Spinal Cord Injury—TNF—atopic dermatitis	4.16e-05	0.000653	CbGpPWpGaD
Erlotinib—ABCB1—Allograft Rejection—CXCL8—atopic dermatitis	4.15e-05	0.000653	CbGpPWpGaD
Erlotinib—NR1I2—Gene Expression—PPARA—atopic dermatitis	4.14e-05	0.000651	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—NFKBIA—atopic dermatitis	4.12e-05	0.000648	CbGpPWpGaD
Erlotinib—JAK3—Immune System—IL18—atopic dermatitis	4.1e-05	0.000644	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—STAT6—atopic dermatitis	4.1e-05	0.000644	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CXCL10—atopic dermatitis	4.08e-05	0.000642	CbGpPWpGaD
Erlotinib—EGFR—EGF/EGFR Signaling Pathway—MAPK8—atopic dermatitis	4.08e-05	0.000641	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—IL2—atopic dermatitis	4.07e-05	0.00064	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—GLB1—atopic dermatitis	4.06e-05	0.000638	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—CCR5—atopic dermatitis	4.04e-05	0.000635	CbGpPWpGaD
Erlotinib—JAK3—Immune System—CD8A—atopic dermatitis	4.04e-05	0.000635	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—TLR2—atopic dermatitis	4e-05	0.000629	CbGpPWpGaD
Erlotinib—MAP2K5—NGF signalling via TRKA from the plasma membrane—IL6—atopic dermatitis	4e-05	0.000629	CbGpPWpGaD
Erlotinib—EGFR—Immune System—KIF3A—atopic dermatitis	4e-05	0.000629	CbGpPWpGaD
Erlotinib—ABCB1—Allograft Rejection—IL1B—atopic dermatitis	3.99e-05	0.000626	CbGpPWpGaD
Erlotinib—ABL1—Immune System—STAT6—atopic dermatitis	3.98e-05	0.000626	CbGpPWpGaD
Erlotinib—ABCB1—Allograft Rejection—IL2—atopic dermatitis	3.97e-05	0.000624	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—CCL11—atopic dermatitis	3.96e-05	0.000622	CbGpPWpGaD
Erlotinib—EGFR—MAPK Signaling Pathway—MAPK8—atopic dermatitis	3.96e-05	0.000622	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—atopic dermatitis	3.93e-05	0.000617	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FCER2—atopic dermatitis	3.9e-05	0.000614	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—ADSL—atopic dermatitis	3.89e-05	0.000612	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—NPS—atopic dermatitis	3.89e-05	0.000611	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TAC1—atopic dermatitis	3.89e-05	0.000611	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CARD11—atopic dermatitis	3.87e-05	0.000608	CbGpPWpGaD
Erlotinib—JAK3—Cytokine Signaling in Immune system—IL6—atopic dermatitis	3.84e-05	0.000604	CbGpPWpGaD
Erlotinib—ALB—Folate Metabolism—TNF—atopic dermatitis	3.81e-05	0.000599	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CXCR3—atopic dermatitis	3.81e-05	0.000599	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—MAPK8—atopic dermatitis	3.8e-05	0.000597	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—GLB1—atopic dermatitis	3.79e-05	0.000595	CbGpPWpGaD
Erlotinib—ALB—Vitamin B12 Metabolism—IL6—atopic dermatitis	3.78e-05	0.000594	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—TNF—atopic dermatitis	3.7e-05	0.000581	CbGpPWpGaD
Erlotinib—ABCB1—head—atopic dermatitis	3.68e-05	0.00838	CbGeAlD
Erlotinib—CYP1B1—Metabolism—ADSL—atopic dermatitis	3.63e-05	0.000571	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCL22—atopic dermatitis	3.63e-05	0.00057	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—CD79A—atopic dermatitis	3.61e-05	0.000568	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IL5—atopic dermatitis	3.61e-05	0.000568	CbGpPWpGaD
Erlotinib—EGFR—Focal Adhesion—MAPK8—atopic dermatitis	3.59e-05	0.000564	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—MAPK8—atopic dermatitis	3.57e-05	0.000561	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor—TNF—atopic dermatitis	3.56e-05	0.000559	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—atopic dermatitis	3.56e-05	0.000559	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CCR3—atopic dermatitis	3.55e-05	0.000558	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—SELE—atopic dermatitis	3.54e-05	0.000557	CbGpPWpGaD
Erlotinib—ABL2—Developmental Biology—IL6—atopic dermatitis	3.54e-05	0.000556	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—PPARA—atopic dermatitis	3.52e-05	0.000554	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CCL5—atopic dermatitis	3.52e-05	0.000552	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—GLB1—atopic dermatitis	3.45e-05	0.000542	CbGpPWpGaD
Erlotinib—EGFR—Immune System—STAT6—atopic dermatitis	3.4e-05	0.000535	CbGpPWpGaD
Erlotinib—EGFR—Spinal Cord Injury—IL6—atopic dermatitis	3.35e-05	0.000527	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—GLB1—atopic dermatitis	3.34e-05	0.000525	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—TNF—atopic dermatitis	3.31e-05	0.00052	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CARD11—atopic dermatitis	3.31e-05	0.00052	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ADSL—atopic dermatitis	3.3e-05	0.000519	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—NGF—atopic dermatitis	3.26e-05	0.000512	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCL27—atopic dermatitis	3.24e-05	0.000508	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—CCR3—atopic dermatitis	3.23e-05	0.000507	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—NPS—atopic dermatitis	3.17e-05	0.000498	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TAC1—atopic dermatitis	3.17e-05	0.000498	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CCR5—atopic dermatitis	3.17e-05	0.000498	CbGpPWpGaD
Erlotinib—EGFR—MAPK Signaling Pathway—TNF—atopic dermatitis	3.13e-05	0.000492	CbGpPWpGaD
Erlotinib—JAK3—Immune System—NFKBIA—atopic dermatitis	3.13e-05	0.000492	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CXCR3—atopic dermatitis	3.11e-05	0.000488	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CXCL10—atopic dermatitis	3.08e-05	0.000484	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling by NGF—IL6—atopic dermatitis	3.08e-05	0.000484	CbGpPWpGaD
Erlotinib—ALB—Folate Metabolism—IL6—atopic dermatitis	3.08e-05	0.000483	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—SLC11A1—atopic dermatitis	3.04e-05	0.000478	CbGpPWpGaD
Erlotinib—ALB—Selenium Micronutrient Network—TNF—atopic dermatitis	3.03e-05	0.000476	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CASP1—atopic dermatitis	3.02e-05	0.000474	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—PPARA—atopic dermatitis	3.01e-05	0.000473	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—IL6—atopic dermatitis	2.98e-05	0.000469	CbGpPWpGaD
Erlotinib—EGFR—Disease—SLC11A1—atopic dermatitis	2.95e-05	0.000464	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL5—atopic dermatitis	2.94e-05	0.000463	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—CD8A—atopic dermatitis	2.91e-05	0.000458	CbGpPWpGaD
Erlotinib—EGFR—Signaling by SCF-KIT—IL6—atopic dermatitis	2.91e-05	0.000457	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCL17—atopic dermatitis	2.9e-05	0.000456	CbGpPWpGaD
Erlotinib—ABCB1—Allograft Rejection—TNF—atopic dermatitis	2.89e-05	0.000454	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—NPS—atopic dermatitis	2.88e-05	0.000452	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—TAC1—atopic dermatitis	2.88e-05	0.000452	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—atopic dermatitis	2.88e-05	0.000452	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL5—atopic dermatitis	2.86e-05	0.000449	CbGpPWpGaD
Erlotinib—MKNK1—Disease—CD4—atopic dermatitis	2.84e-05	0.000446	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—TNF—atopic dermatitis	2.83e-05	0.000444	CbGpPWpGaD
Erlotinib—JAK3—Immune System—CASP8—atopic dermatitis	2.83e-05	0.000444	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—CXCR3—atopic dermatitis	2.82e-05	0.000443	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling of activated FGFR—IL6—atopic dermatitis	2.78e-05	0.000437	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	2.76e-05	0.000434	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—NFKBIA—atopic dermatitis	2.75e-05	0.000433	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB4—IL6—atopic dermatitis	2.74e-05	0.00043	CbGpPWpGaD
Erlotinib—ABL1—Immune System—TLR2—atopic dermatitis	2.73e-05	0.000429	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—CXCL8—atopic dermatitis	2.69e-05	0.000423	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—NFKBIA—atopic dermatitis	2.69e-05	0.000422	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—IL5—atopic dermatitis	2.68e-05	0.000422	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL5—atopic dermatitis	2.67e-05	0.00042	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—SLC11A1—atopic dermatitis	2.66e-05	0.000419	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CCL5—atopic dermatitis	2.65e-05	0.000417	CbGpPWpGaD
Erlotinib—EGFR—Downstream signal transduction—IL6—atopic dermatitis	2.62e-05	0.000411	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR—IL6—atopic dermatitis	2.6e-05	0.000409	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—atopic dermatitis	2.59e-05	0.000408	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB2—IL6—atopic dermatitis	2.59e-05	0.000407	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—MAPK8—atopic dermatitis	2.59e-05	0.000407	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KIF3A—atopic dermatitis	2.59e-05	0.000406	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CASP1—atopic dermatitis	2.58e-05	0.000405	CbGpPWpGaD
Erlotinib—EGFR—DAP12 signaling—IL6—atopic dermatitis	2.58e-05	0.000405	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—IL2—atopic dermatitis	2.57e-05	0.000404	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CD79A—atopic dermatitis	2.57e-05	0.000403	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CXCL10—atopic dermatitis	2.51e-05	0.000395	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—CASP8—atopic dermatitis	2.48e-05	0.00039	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GLB1—atopic dermatitis	2.47e-05	0.000388	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—NGF—atopic dermatitis	2.46e-05	0.000386	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—CXCL8—atopic dermatitis	2.44e-05	0.000384	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL5—atopic dermatitis	2.44e-05	0.000384	CbGpPWpGaD
Erlotinib—ALB—Selenium Micronutrient Network—IL6—atopic dermatitis	2.44e-05	0.000384	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—IL6—atopic dermatitis	2.43e-05	0.000381	CbGpPWpGaD
Erlotinib—EGFR—DAP12 interactions—IL6—atopic dermatitis	2.43e-05	0.000381	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR in disease—IL6—atopic dermatitis	2.43e-05	0.000381	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR—IL6—atopic dermatitis	2.4e-05	0.000378	CbGpPWpGaD
Erlotinib—JAK3—Immune System—IFNG—atopic dermatitis	2.4e-05	0.000377	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CCR5—atopic dermatitis	2.39e-05	0.000375	CbGpPWpGaD
Erlotinib—ABCG2—Transmembrane transport of small molecules—PPARA—atopic dermatitis	2.39e-05	0.000375	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR in Cancer—IL6—atopic dermatitis	2.38e-05	0.000374	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—IL6—atopic dermatitis	2.37e-05	0.000373	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ADSL—atopic dermatitis	2.37e-05	0.000372	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—NFKBIA—atopic dermatitis	2.35e-05	0.00037	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCL11—atopic dermatitis	2.34e-05	0.000368	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CMA1—atopic dermatitis	2.34e-05	0.000368	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—IL2—atopic dermatitis	2.34e-05	0.000367	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GLB1—atopic dermatitis	2.33e-05	0.000367	CbGpPWpGaD
Erlotinib—EGFR—Immune System—TLR2—atopic dermatitis	2.33e-05	0.000366	CbGpPWpGaD
Erlotinib—JAK3—Immune System—CD4—atopic dermatitis	2.32e-05	0.000365	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—CXCL10—atopic dermatitis	2.28e-05	0.000358	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—NFKBIA—atopic dermatitis	2.26e-05	0.000355	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ADSL—atopic dermatitis	2.24e-05	0.000351	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—STAT6—atopic dermatitis	2.2e-05	0.000346	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CD79A—atopic dermatitis	2.19e-05	0.000344	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CCL5—atopic dermatitis	2.16e-05	0.00034	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—IL6—atopic dermatitis	2.15e-05	0.000338	CbGpPWpGaD
Erlotinib—JAK3—Immune System—IL1B—atopic dermatitis	2.14e-05	0.000337	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GLB1—atopic dermatitis	2.14e-05	0.000336	CbGpPWpGaD
Erlotinib—JAK3—Immune System—IL2—atopic dermatitis	2.13e-05	0.000335	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GLB1—atopic dermatitis	2.13e-05	0.000334	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—CASP8—atopic dermatitis	2.12e-05	0.000333	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL18—atopic dermatitis	2.1e-05	0.00033	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—IL2—atopic dermatitis	2.08e-05	0.000327	CbGpPWpGaD
Erlotinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—atopic dermatitis	2.08e-05	0.000326	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CD8A—atopic dermatitis	2.07e-05	0.000325	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ADSL—atopic dermatitis	2.05e-05	0.000322	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—CD4—atopic dermatitis	2.04e-05	0.00032	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ADSL—atopic dermatitis	2.04e-05	0.00032	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—NFKBIA—atopic dermatitis	2.02e-05	0.000318	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—NGF—atopic dermatitis	2e-05	0.000315	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—IL2—atopic dermatitis	1.99e-05	0.000313	CbGpPWpGaD
Erlotinib—JAK3—Immune System—MAPK8—atopic dermatitis	1.96e-05	0.000309	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—CCL5—atopic dermatitis	1.96e-05	0.000308	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CCR5—atopic dermatitis	1.95e-05	0.000306	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CXCL8—atopic dermatitis	1.91e-05	0.000301	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCR3—atopic dermatitis	1.91e-05	0.0003	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GLB1—atopic dermatitis	1.86e-05	0.000293	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—IL2—atopic dermatitis	1.83e-05	0.000288	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—atopic dermatitis	1.8e-05	0.000283	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL18—atopic dermatitis	1.79e-05	0.000282	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ADSL—atopic dermatitis	1.79e-05	0.000281	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—CCR5—atopic dermatitis	1.77e-05	0.000278	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CD8A—atopic dermatitis	1.77e-05	0.000278	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GLB1—atopic dermatitis	1.76e-05	0.000276	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—IL6—atopic dermatitis	1.75e-05	0.000275	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—CD4—atopic dermatitis	1.74e-05	0.000274	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—MAPK8—atopic dermatitis	1.73e-05	0.000271	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	1.7e-05	0.000267	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NPS—atopic dermatitis	1.7e-05	0.000267	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TAC1—atopic dermatitis	1.7e-05	0.000267	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—MAPK8—atopic dermatitis	1.68e-05	0.000265	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ADSL—atopic dermatitis	1.68e-05	0.000264	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—CD4—atopic dermatitis	1.67e-05	0.000263	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CXCR3—atopic dermatitis	1.67e-05	0.000262	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—IL6—atopic dermatitis	1.65e-05	0.00026	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—NFKBIA—atopic dermatitis	1.65e-05	0.000259	CbGpPWpGaD
Erlotinib—ABL1—Immune System—NFKBIA—atopic dermatitis	1.6e-05	0.000252	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL5—atopic dermatitis	1.58e-05	0.000248	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	1.56e-05	0.000245	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	1.55e-05	0.000243	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—TNF—atopic dermatitis	1.55e-05	0.000243	CbGpPWpGaD
Erlotinib—MKNK1—Disease—IL6—atopic dermatitis	1.54e-05	0.000241	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—IL6—atopic dermatitis	1.5e-05	0.000235	CbGpPWpGaD
Erlotinib—EGFR—Disease—CCR5—atopic dermatitis	1.49e-05	0.000234	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GLB1—atopic dermatitis	1.49e-05	0.000234	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—MAPK8—atopic dermatitis	1.48e-05	0.000232	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—PPARA—atopic dermatitis	1.47e-05	0.000232	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CASP8—atopic dermatitis	1.45e-05	0.000227	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CXCL8—atopic dermatitis	1.44e-05	0.000227	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—atopic dermatitis	1.43e-05	0.000224	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ADSL—atopic dermatitis	1.43e-05	0.000224	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IL2—atopic dermatitis	1.38e-05	0.000217	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—IL6—atopic dermatitis	1.37e-05	0.000216	CbGpPWpGaD
Erlotinib—EGFR—Immune System—NFKBIA—atopic dermatitis	1.37e-05	0.000215	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CXCL10—atopic dermatitis	1.35e-05	0.000212	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—TNF—atopic dermatitis	1.32e-05	0.000208	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PPARA—atopic dermatitis	1.32e-05	0.000207	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—PPARA—atopic dermatitis	1.29e-05	0.000203	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MAPK8—atopic dermatitis	1.27e-05	0.0002	CbGpPWpGaD
Erlotinib—JAK3—Immune System—IL6—atopic dermatitis	1.25e-05	0.000197	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—IL6—atopic dermatitis	1.25e-05	0.000196	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CASP8—atopic dermatitis	1.24e-05	0.000194	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IFNG—atopic dermatitis	1.23e-05	0.000193	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PPARA—atopic dermatitis	1.23e-05	0.000193	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CD4—atopic dermatitis	1.19e-05	0.000187	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CXCL8—atopic dermatitis	1.18e-05	0.000185	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCL5—atopic dermatitis	1.16e-05	0.000182	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GLB1—atopic dermatitis	1.15e-05	0.00018	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL2—atopic dermatitis	1.12e-05	0.000177	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PPARA—atopic dermatitis	1.12e-05	0.000176	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—IL6—atopic dermatitis	1.1e-05	0.000173	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ADSL—atopic dermatitis	1.1e-05	0.000173	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL1B—atopic dermatitis	1.1e-05	0.000172	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL2—atopic dermatitis	1.09e-05	0.000172	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	1.08e-05	0.00017	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—IL6—atopic dermatitis	1.08e-05	0.000169	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NGF—atopic dermatitis	1.07e-05	0.000169	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—CXCL8—atopic dermatitis	1.07e-05	0.000168	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—IL6—atopic dermatitis	1.07e-05	0.000168	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IFNG—atopic dermatitis	1.05e-05	0.000165	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCR5—atopic dermatitis	1.04e-05	0.000164	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MAPK8—atopic dermatitis	1.04e-05	0.000163	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—IL2—atopic dermatitis	1.03e-05	0.000161	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL2—atopic dermatitis	1.02e-05	0.000161	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CD4—atopic dermatitis	1.01e-05	0.000159	CbGpPWpGaD
Erlotinib—ABL1—Immune System—MAPK8—atopic dermatitis	1.01e-05	0.000158	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—IL6—atopic dermatitis	9.42e-06	0.000148	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL1B—atopic dermatitis	9.37e-06	0.000147	CbGpPWpGaD
Erlotinib—EGFR—Disease—CD4—atopic dermatitis	9.37e-06	0.000147	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL2—atopic dermatitis	9.34e-06	0.000147	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NFKBIA—atopic dermatitis	8.86e-06	0.000139	CbGpPWpGaD
Erlotinib—EGFR—Immune System—MAPK8—atopic dermatitis	8.59e-06	0.000135	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IL6—atopic dermatitis	8.11e-06	0.000127	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PPARA—atopic dermatitis	8.01e-06	0.000126	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PPARA—atopic dermatitis	7.57e-06	0.000119	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PPARA—atopic dermatitis	6.94e-06	0.000109	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PPARA—atopic dermatitis	6.9e-06	0.000108	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL6—atopic dermatitis	6.61e-06	0.000104	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL6—atopic dermatitis	6.42e-06	0.000101	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CXCL8—atopic dermatitis	6.32e-06	9.93e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PPARA—atopic dermatitis	6.05e-06	9.5e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL2—atopic dermatitis	6.04e-06	9.49e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL6—atopic dermatitis	6.01e-06	9.44e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PPARA—atopic dermatitis	5.7e-06	8.95e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MAPK8—atopic dermatitis	5.56e-06	8.73e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL6—atopic dermatitis	5.49e-06	8.62e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—IL6—atopic dermatitis	5.07e-06	7.96e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PPARA—atopic dermatitis	4.83e-06	7.58e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PPARA—atopic dermatitis	3.73e-06	5.85e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL6—atopic dermatitis	3.55e-06	5.58e-05	CbGpPWpGaD
